00:14 , Dec 28, 2017 |  BC Extra  |  Company News

Management tracks: Vivus, Peregrine

Cardiovascular, metabolic and pulmonary company Vivus Inc. (NASDAQ:VVUS) said CEO Seth Fischer will step down. Thomas King, a director, will serve as interim CEO as the company seeks a permanent replacement. King was president and...
21:41 , Sep 29, 2017 |  BC Week In Review  |  Financial News

Engage, Integra raise venture financings

Epilepsy play Engage Therapeutics Inc. (Summit, N.J.) and life science investment company Integra Holdings (Jerusalem, Israel) announced venture financings, raising nearly $50 million. Engage raised $23 million on Sept. 27 in a series A round...
00:04 , Sep 28, 2017 |  BC Extra  |  Financial News

Venture roundup: Engage, Integra

On Wednesday, epilepsy play Engage Therapeutics Inc. (Summit, N.J.) and life science investment company Integra Holdings (Jerusalem, Israel) announced venture financings, raising nearly $50 million. Engage raised $23 million in a series A round led...
07:00 , May 23, 2016 |  BC Week In Review  |  Company News

Alexza, Ferrer deal

Grupo Ferrer’s Ferrer Pharma subsidiary will acquire Alexza for $0.90 per share in cash. The deal values Alexza at $19.6 million based on 21.7 million shares outstanding on May 11. Alexza shareholders will also receive...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Clinical News

Staccato alprazolam: Interim Phase IIa data

Interim data from 3 epileptics with acute repetitive seizures in a double-blind, crossover, U.S. Phase IIa trial showed that single doses of 0.5, 1 and 2 mg inhaled AZ-002 led to dose-related reductions in mean...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Company News

Alexza, Teva deal

Alexza will regain U.S. rights to Adasuve loxapine from Teva, effective Jan. 1, 2016. Alexza, which granted Teva U.S rights in 2013, said it plans to identify a new U.S. commercial partner for the product....
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Alexza drug delivery, neurology news

Alexza retained Guggenheim Securities to explore strategic options, including the sale or disposition of one or more corporate assets, a strategic business combination, partnership or other transactions. Alexza’s Adasuve loxapine -- loxapine delivered by the...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Company News

Alexza, Ferrer deal

The companies added the Middle East and North Africa region, Korea, the Philippines and Thailand to a 2011 deal granting Grupo Ferrer exclusive rights to commercialize Adasuve loxapine. Grupo Ferrer now has rights in the...
01:07 , Jul 15, 2015 |  BC Extra  |  Company News

Management tracks

Baxalta Inc. (NYSE:BXLT) named Jacopo Leonardi EVP and president of immunology. Leonardi most recently was general manager of U.S. Hemophilia at the Baxter BioScience unit of Baxter International Inc. (NYSE:BAX). Antares Pharma Inc. (NASDAQ:ATRS) hired...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Clinical News

Staccato alprazolam: Phase IIa started

Alexza began a double-blind, placebo-controlled, crossover, U.S. Phase IIa trial to evaluate a single dose of 0.5, 1 and 2 mg inhaled Staccato in about 6 patients. Alexza Pharmaceuticals Inc. (NASDAQ:ALXA), Mountain View, Calif.  ...